- In-licensed patented technology from University of New Hampshire for production of hyperpolarized xenon-129
- Filed Investigational New Drug status with the US FDA for hyperpolarized xenon-129
- Determined that drug research for regulatory advancement could proceed under FDA safe-harbor
- Completed Phase I studies of 30 healthy volunteers in 2006, advancing to Phase II
- Assembled world class development team
- Scaled up the productive output of hyperpolarized xenon-129 ten-fold
- Applied new technology to SEOP production of hyperpolarized helium-3, improving production rates ten-fold
- Raised $7M in non-dilutive capital through competitive research grant proposals
- Fifth patent awarded strengthens Xemed’s worldwide patent portfolio
- Secured collaboration with first pharmaceutical partner to evaluate imaging biomarkers for cystic fibrosis severity
- Established collaboration to evaluate MagniXene®-guided bronchial thermoplasty
- Expanding MagniXene® Imaging Network by negotiating with six new Centers for temporary and long-term installations of XeBox-E10